NCT02376699: Safety Study of SEA-CD40 in Cancer Patients

NCT02376699
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Active central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT02376699

Comments are closed.

Up ↑